B.Riley Financial Remains a Buy on Zynex (ZYXI)
In a report issued on January 13, Marc Wiesenberger from B.Riley Financial reiterated a Buy rating on Zynex (ZYXI), with a price target of $23.00. The company’s shares closed last Tuesday at $18.05.
According to TipRanks.com, Wiesenberger is a top 100 analyst with an average return of 76.4% and a 85.0% success rate. Wiesenberger covers the Technology sector, focusing on stocks such as Lightpath Technologies, Wireless Telecom Group, and Insight Enterprises.
Currently, the analyst consensus on Zynex is a Strong Buy with an average price target of $24.63, implying a 43.4% upside from current levels. In a report issued on December 30, Northland Securities also assigned a Buy rating to the stock with a $22.50 price target.
See today’s analyst top recommended stocks >>
Based on Zynex’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $20.03 million and net profit of $1.33 million. In comparison, last year the company earned revenue of $11.82 million and had a net profit of $2.03 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. The company also develops a new blood volume monitor for use in hospitals and surgery centers. Zynex was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.